Eriko Hamada

Eriko Hamada

Auto-generated profile, based on publicly available information

Eriko Hamada

Department of Respiratory Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2024 in Respiratory Medicine
Verified
Journal Article
Closed access
YFYukio Fujita
Yukio Fujita
MYMotoo Yamauchi
Motoo Yamauchi
EHEriko Hamada
Eriko Hamada
AIAzusa Ikegami
Azusa Ikegami
RSRyutaro Shirahama
Ryutaro Shirahama
SMSHIGEO MURO
SHIGEO MURO

18 November 2022 in Respirology Case Reports
Verified
Journal Article
Open access
EHEriko Hamada
Eriko Hamada
YYYoshifumi Yamamoto
Yoshifumi Yamamoto
YOYosuke Okuda
Yosuke Okuda
KSKazuhiro Sakaguchi
Kazuhiro Sakaguchi
KSKentaro Suzuki
Kentaro Suzuki
SMSHIGEO MURO
SHIGEO MURO
A 28‐year‐old man with ankylosing spondylitis (AS) who was treated with a tumour necrosis factor‐alpha (TNF‐α) inhibitor, adalimumab, presented with newly detected multiple bilateral pulmonary nodules on chest computed tomography (CT). We suspected bacterial infection, including those caused by acid‐fast bacilli, or adalimumab‐related condition, such as sarcoidosis. After adalimumab cessation, no resolution of the pulmonary shadows was observed. Moreover, pulmonary cavitation appeared on chest CT at 7 weeks, prompting surgical lung biopsy. Acid‐fast bacteria culture of the lung tissue showed negative results. Pathological examination suggested that confluent granulomas associated with sarcoidosis might have obstructed the blood vessels, causing necrosis and lung cavitation. Consequently, prednisolone was initiated, and these shadows were reduced. After administering anti‐interleukin (IL)‐17A antibody for treatment of AS and prednisolone withdrawal, these shadows were not exacerbated. TNF‐α inhibitor‐induced sarcoidosis could cause cavitary lesions due to vascular invasion of granulomas.

21 October 2022 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
ETErika Tarasco
Erika Tarasco
AKAnne Sophie von Krogh
Anne Sophie von Krogh
RHRadomira Hrdlickova
Radomira Hrdlickova
TBThomas R. Braschler
Thomas R. Braschler
TITeresa Iwaniec
Teresa Iwaniec
JHJohanna Anna Kremer Hovinga
Johanna Anna Kremer Hovinga
Severe COVID‐19 is associated with an important increase of von Willebrand factor and mild lowering of ADAMTS13 activity that may, in the presence of a strong inflammatory reaction, increase the risk of acute thrombotic thrombocytopenic purpura (TTP). Although acute episodes of immune‐mediated TTP associated with COVID‐19 or SARS‐CoV‐2 vaccination have been reported, data about clinical evolution of hereditary TTP (hTTP) during the pandemic are scarce. We conducted a survey among adult patients of the International Hereditary TTP Registry about SARS‐CoV‐2 vaccination, COVID‐19, and occurrence of acute hTTP episodes. Of 122 adult hTTP patients invited to participate, 86 (70.5%) responded. Sixty‐five had been vaccinated (75.6%), of which 14 had received in addition a booster, resulting in 139 individual vaccine shots. Although vaccinations in patients on plasma prophylaxis were done within 1 week of the last plasma infusion, all 23 patients treated with plasma on demand were vaccinated without prior plasma infusions. One patient on uninterrupted weekly plasma infusions presented within 3 days from his second vaccination with neurological symptoms and computed tomography scan 9 days later showed subacute ischemic/hemorrhagic frontal lobe infarction. A second male patient developed acute myocarditis after his second dose of mRNA‐1273 vaccine. Twelve (14%) patients had COVID‐19, associated with an acute hTTP episode in three of them: one patient had a transient ischemic attack, one a stroke, and a pregnant woman was hospitalized to intensify plasma treatment. The risk of an acute episode triggered by COVID‐19 seems higher than following vaccination in hTTP patients, who can be safely vaccinated against SARS‐CoV‐2.

1 July 2025 in Respiratory Investigation
Verified
Journal Article
Closed access
JIJiro Ito
Jiro Ito
TYToshiki Yokoyama
Toshiki Yokoyama
ATAiko Tanaka
Aiko Tanaka
RSRyutaro Seo
Ryutaro Seo
KTKeisuke Tomii
Keisuke Tomii
YKYasuhiro Kondoh
Yasuhiro Kondoh

1 July 2024 in Sleep and Breathing
Verified
Journal Article
Open access
PDF file
MYMotoo Yamauchi
Motoo Yamauchi
YMYasutaka Moritsuchi
Yasutaka Moritsuchi
EHEriko Hamada
Eriko Hamada

Verified
Journal Article
Open access
PDF file
EHEriko Hamada
Eriko Hamada
TCThomaz Fleury Curado
Thomaz Fleury Curado
KSKingman Strohl
Kingman Strohl
YHYee-Hsee Hsieh
Yee-Hsee Hsieh
Background/Objectives: Upper airway patency is a key pathophysiological factor in obstructive sleep apnea (OSA). Research has primarily focused on the role of the genioglossus muscle in maintaining airway patency in OSA. However, hypoglossal nerve stimulation (HNS) therapy, which activates the genioglossus muscle, has been associated with poor outcomes in patients with lateral oropharyngeal collapse. The stylopharyngeus muscle is an upper airway dilator muscle that supports the lateral pharyngeal wall. Its role in maintaining upper airway patency and its effect on normal respiratory airflow is unclear. We hypothesize that bilateral transection of the stylopharyngeus muscles disrupts normal breathing. Currently, no animal model depicting lateral pharyngeal collapse has been reported. This study aims to introduce a novel rodent model with bilateral transection of the stylopharyngeus muscles to examine its effect on respiratory airflow and tracing. Methods: Adult male Sprague Dawley rats were divided into two groups: (1) bilateral stylopharyngeus muscle transection (n = 4) and (2) sham surgery (n = 2). Under anesthesia, the stylopharyngeus muscle was transected bilaterally in the transection group, while only exposure of the muscle was performed in the sham group. Respiratory airflow was measured using whole-body plethysmography before and after surgery, and airflow tracings were analyzed. Results: Significant alterations in respiratory airflow and tracings, particularly a flattening in inspiratory flow and sharp expiratory peaks, were observed on the first post-operative day in the transection group. The flattening of the inspiratory flow persisted over 3 days. No significant changes were noted in the sham group. Conclusions: Bilateral stylopharyngeus muscle transection alters normal airflow in a conscious rodent model, supporting the hypothesis that stylopharyngeus muscle plays a vital role in shaping respiratory airflow. The flattening of the inspiratory airflow is an indication of flow limitations through the upper airway patency due to the loss of stylopharyngeus function.